Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study
Damiano Baroncini, G. Coniglio, Daniela Cargnelutti(Multiple Sclerosis Foundation), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Angelo Ghezzi, Lucia Moiola(Vita-Salute San Raffaele University), Girolama Alessandra Marfia(Erasmus University Rotterdam), María Trojano(University of Bari Aldo Moro), Claudio Gasperini(Nini Hospital), Alice Laroni(Azienda Ospedaliera di Padova), Sarah Rasia(Vita-Salute San Raffaele University), Ruggero Capra(Presidio Ospedaliero), Graziella Callari(Fondazione Istituto G. Giglio di Cefalù), Antonio Uccelli(Istituti di Ricovero e Cura a Carattere Scientifico), Roberta Lanzillo(University of Naples Federico II), Monica Margoni(Vita-Salute San Raffaele University), Antonio Ianniello(Sapienza University of Rome), Marta Simone(University of Bari Aldo Moro), Paolo Gallo(University of Padua), Massimiliano Calabrese(University of Verona), Francesco Patti(University of Catania), Marco Capobianco(Ospedale San Luigi Gonzaga), Carlo Pozzilli(Sapienza University of Rome), Giacomo Lus(University of Campania "Luigi Vanvitelli"), Antonio Gallo(University of Campania "Luigi Vanvitelli"), Vincenzo Brescia Morra(Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari), Clara Guaschino, Luigi Maria Edoardo Grimaldi(Fondazione Istituto G. Giglio di Cefalù), Giancarlo Comi(University of Milan), Diego Centonze(University of Rome Tor Vergata), Maura Danni(Multiple Sclerosis Foundation), Massimo Filippi(Vita-Salute San Raffaele University)
Cited by 32
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k